Sinclair Dunlop - Jun 23, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for A. Sinclair Dunlop
Stock symbol
APLS
Transactions as of
Jun 23, 2022
Transactions value $
-$675,000
Form type
4
Date filed
6/24/2022, 05:15 PM
Previous filing
Apr 25, 2022
Next filing
Jun 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$675K -15K -4.99% $45.00 286K Jun 23, 2022 Indirect Owner (Epidarex) F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.